logo-loader
RNS
viewAvacta Group PLC

Director/PDMR Shareholding

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .y{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.y{}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; text-align: center}span.cr{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%}span.cp{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; margin-right: 5.0pt; text-align: right}span.cn{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif"}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; text-align: center}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 6.0pt; text-align: center} p.cy{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:115%}p.cz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.ci{font-size:10.0pt; font-family:"Arial","sans-serif"}span.ch{font-size:10.0pt; font-family:"Arial","sans-serif";color:black}span.cf{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}p.da{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.ce{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}span.cc{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}p.db{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; text-align: justify} table.dc{width:460.4pt;margin-left:-5.1pt;border-collapse:collapse}tr.bx{height:43.9pt}td.ca{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}td.by{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}span.bz{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}tr.br{height:99.2pt}td.bw{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt}td.bs{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt}p.dd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; text-align: justify; text-decoration: underline}span.de{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; line-height: 115%; text-decoration: none} span.bt{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}td.bp{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt}span.bq{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}td.bj{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt}p.df{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height:115%}span.bo{font-size:10.0pt;line-height:115%;font-family:"Times New Roman","serif"}span.bn{font-family: "Arial","sans-serif"; font-size: 10.0pt; line-height: 115%; text-decoration: underline}p.dg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; text-decoration: underline}span.bk{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:windowtext}p.dh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin: 0cm; margin-bottom: .0001pt; text-align: justify} span.bh{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black}p.di{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; line-height:115%}p.dj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; line-height:115%}span.dk{font-family:"Times New Roman","serif";font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}p.dl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.bd{font-family:"Arial","sans-serif"}span.bc{font-size:14.0pt;font-family:"Arial","sans-serif"}table.dm{margin-left:-5.4pt;border-collapse:collapse;border:none}td.az{width:37.15pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt} span.bb{font-size: 9.0pt;font-family:"Arial","sans-serif"}td.ax{width:403.1pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.do{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt}span.ay{font-size:9.0pt;font-family: "Arial","sans-serif"}td.av{width:37.15pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.dp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:5.0pt;margin-right:0cm;margin-bottom: 5.0pt;margin-left:0cm}td.au{width:130.95pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.at{width:261.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.as{width:403.1pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.dq{border-collapse:collapse;border:none} tr.ap{height:4.2pt}td.aq{border:none;padding:0cm 5.4pt 0cm 5.4pt;height:4.2pt}span.ar{font-size:9.0pt;font-family:"Arial","sans-serif"}p.dr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 5.0pt; margin-left: 18.0pt; margin-right: 0cm; margin-top: 5.0pt; text-indent: -18.0pt}td.am{width:130.95pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.aj{width:261.6pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.v,li.v,div.v{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Verdana","sans-serif";color:black;}td.ak{width:146.8pt;border:none;padding:0cm 5.4pt 0cm 5.4pt; height:4.2pt}span.al{font-size:9.0pt}span.ai{font-size:9.0pt;font-family: "Arial","sans-serif";color:black} span.ah{font-size:10.0pt;font-family:"Arial","sans-serif"}td.ag{width:119.6pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.af{width:119.65pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ad{width:119.6pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}span.ae{font-size:10.0pt;font-family: "Arial","sans-serif"}td.ac{width:119.65pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ds{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:5.0pt;margin-right:0cm; margin-bottom:5.0pt;margin-left:18.0pt;text-indent:-18.0pt}span.ab{font-size:9.0pt;font-family:Symbol}p.dt{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:36.0pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:5.0pt;margin-right:0cm; margin-bottom:5.0pt;margin-left:18.0pt;text-indent:-18.0pt} /**/
RNS Number : 8670L
Avacta Group PLC
02 January 2019
 

 

 

02 January 2019

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Director's Dealing

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that its Chief Financial Officer, Tony Gardiner, has purchased on 31 December 2018 8,196 ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 30.5 pence per Ordinary Share.

 

Following this transaction, Tony Gardiner's total beneficial interest in the Company is 8,196 Ordinary Shares, representing less than 0.1% of Avacta's issued share capital. In addition, Tony Gardiner has a joint interest in 150,000 Ordinary Shares; such Ordinary Shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.

 

 

- Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern / Sunila de Silva - ECM

 

WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope / Ben Turner

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey (Financial Media and IR)

Sarah Hollins

Harriet Jackson

Tel: +44 (0) 203 621 4120
www.turnerpope.com

 

Tel: +44 (0)7787 502 947

www.zymecommunications.com 

 

 

Tel: +44 (0)7764 947137

Tel: +44 (0)7544 275882

[email protected]

 

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tony Gardiner

2.               

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

 

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Avacta Group Plc

b)

LEI

2138009U3EG31OPMGH36

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

ordinary shares of 10p

 

Identification code

GB00BYYW9G87

b)

Nature of the transaction

 

Purchase of Ordinary Shares

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

30.5 pence

8,196

 

d)

Aggregated information:

·      Aggregated volume

·      Price

 

See above

e)

Date of the transaction

31 December 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHCKDDQFBKDADK

Quick facts: Avacta Group PLC

Price: 16.25

Market: AIM
Market Cap: £18.88 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19